EYEiji Yamato

Eiji Yamato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eiji Yamato has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Hikaru Matsuda

    1 shared publication
  • Hirofumi Makino

    1 shared publication
  • Hironori Nakagami

    1 shared publication
  • Hitonobu Tomoike

    From the Research Institute (K.Komamura, R.T., Y.S., K.Kangawa); Division of Cardiology (K.Komamura, H.T., M.K., K.Miyatake), National Cardiovascular Center; Kyoto Institute of Technology (J.M., K.Matsumoto, E.Y., T.Nakamura), Osaka University, Graduate School of Medicine; Department of Cardiovascular Surgery (T.Nakatani, S.K.), National Cardiovascular Center, Suita, Japan

    1 shared publication
  • Jun-Ichi Miyazaki

    Division of Stem Cell Regulation Research, Osaka University Graduate School of Medicine, Suita, Japan

    1 shared publication
  • Junya Azuma

    1 shared publication

Latest Publications

  • Treatment of Dilated Cardiomyopathy With Electroporation of Hepatocyte Growth Factor Gene Into Skeletal Muscle

    by Kazuo Komamura, Rie Tatsumi, Jun-Ichi Miyazaki, Kunio Matsumoto, Eiji Yamato, Toshikazu Nakamura, Yoshito Shimizu, Takeshi Nakatani, Soichiro Kitamura, Hitonobu Tomoike, et al.

    Hepatocyte growth factor (HGF) is a potent angiogenic and antifibrotic factor. Cardioprotective effects of HGF for idiopathic dilated cardiomyopathy were examined in hamsters with electroporation of plasmid DNA into skeletal muscle. We used hamster skeletal muscle as a protein producer of HGF gene. A plasmid vector encoding HGF (HGF group, n=12) or empty plasmid (placebo group, n=12) was transferred with in vivo electroporation into tibialis anterior muscles of hamsters with inherited dilated cardiomyopathy (TO-2 strain). The HGF group had greater serum HGF levels (21.6±2.2 versus 0.11±0.07 ng/mL, P P P P P 2 , P P <0.05) than did the placebo group. Exogenous HGF might improve the deleterious changes in myocardial function and structure in the hamster with dilated cardiomyopathy. Systemic delivery of gene products with in vivo electroporation into skeletal muscle seemed to be an alternative means of direct gene delivery.